Author Affiliation: Department of Pharmacology and Center for Translational Medicine, Temple University, Philadelphia, Pennsylvania.
In a recent article published in this journal, Galasko et al1 provided evidence in support of the idea that short-term antioxidant treatment does not influence cerebrospinal fluid (CSF) biomarkers related to amyloid-β or tau pathology. However, the same antioxidants (vitamin E, vitamin C, and α-lipoic acid), but not coenzyme Q alone, result in a small (19%) but significant reduction in CSF F2-isoprostanes, a marker of lipid peroxidation, and a significant cognitive decline as measured by the Mini-Mental State Examination. Because of this association, the authors raise a note of caution in case and “if a longer-term clinical trial of this antioxidant combination is considered.”
Praticò D. Antioxidants for Alzheimer Disease. JAMA Neurol. 2013;70(2):270–271. doi:10.1001/jamaneurol.2013.613
Neurology in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.